These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 32969816)
1. sQuiz your knowledge: Polycyclic annular plaques on the trunk following dutasteride treatment. Ruiz-Villaverde R; Ayen-Rodriguez A; Llamas-Molina JM Eur J Dermatol; 2020 Aug; 30(4):452-453. PubMed ID: 32969816 [No Abstract] [Full Text] [Related]
2. Angioedema-like contact dermatitis caused by mesotherapy with dutasteride. Magdaleno-Tapial J; Valenzuela-Oñate C; García-Legaz-Martínez M; Martínez-Domenech Á; Alonso-Carpio M; Talamantes CS; Zaragoza-Ninet MG; Zaragoza-Ninet V Contact Dermatitis; 2020 Sep; 83(3):246-247. PubMed ID: 32356373 [No Abstract] [Full Text] [Related]
3. Adverse Effects of 5-Alpha Reductase Inhibitor Therapy in Men With Androgenetic Alopecia: Is There Cause for Concern? Arias-Santiago S; Camacho-Martínez FM Actas Dermosifiliogr; 2016 Nov; 107(9):709-711. PubMed ID: 27436801 [No Abstract] [Full Text] [Related]
4. 5α-Reductase inhibitors in men aged 50 years or older with androgenetic alopecia: A retrospective study. Kang MJ; Choi JY; Sim WY; Lew BL J Am Acad Dermatol; 2021 Jan; 84(1):172-173. PubMed ID: 32320771 [No Abstract] [Full Text] [Related]
5. 5-Alpha reductase inhibitors in androgenetic alopecia: Shifting paradigms, current concepts, comparative efficacy, and safety. Dhurat R; Sharma A; Rudnicka L; Kroumpouzos G; Kassir M; Galadari H; Wollina U; Lotti T; Golubovic M; Binic I; Grabbe S; Goldust M Dermatol Ther; 2020 May; 33(3):e13379. PubMed ID: 32279398 [TBL] [Abstract][Full Text] [Related]
6. Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male Androgenetic Alopecia: A Systematic Review and Meta-analysis. Lee S; Lee YB; Choe SJ; Lee WS Acta Derm Venereol; 2019 Jan; 99(1):12-17. PubMed ID: 30206635 [TBL] [Abstract][Full Text] [Related]
7. Prospective randomized study of sexual function in men taking dutasteride for the treatment of androgenetic alopecia. Tsai TF; Choi GS; Kim BJ; Kim MB; Ng CF; Kochhar P; Jasper S; Brotherton B; Orban B; Lulic Z J Dermatol; 2018 Jul; 45(7):799-804. PubMed ID: 29667763 [TBL] [Abstract][Full Text] [Related]
8. Long-term safety and efficacy of dutasteride in the treatment of male patients with androgenetic alopecia. Tsunemi Y; Irisawa R; Yoshiie H; Brotherton B; Ito H; Tsuboi R; Kawashima M; Manyak M; J Dermatol; 2016 Sep; 43(9):1051-8. PubMed ID: 26893187 [TBL] [Abstract][Full Text] [Related]
9. Dutasteride in Androgenetic Alopecia: An Update. Arif T; Dorjay K; Adil M; Sami M Curr Clin Pharmacol; 2017; 12(1):31-35. PubMed ID: 28294070 [TBL] [Abstract][Full Text] [Related]
10. Sexual side effects of 5-α-reductase inhibitors finasteride and dutasteride: A comprehensive review. Fertig RM; Gamret AC; Darwin E; Gaudi S Dermatol Online J; 2017 Nov; 23(11):. PubMed ID: 29447628 [TBL] [Abstract][Full Text] [Related]
11. Comments concerning the real risk of sexual adverse events secondary to the use of 5-ARIs. Pirozzi Farina F; Pischedda A Arch Ital Urol Androl; 2016 Jan; 87(4):312-6. PubMed ID: 26766804 [TBL] [Abstract][Full Text] [Related]
13. Sexual Problems of Men With Androgenic Alopecia Treated With 5-Alpha Reductase Inhibitors. Coskuner ER; Ozkan B; Culha MG Sex Med Rev; 2019 Apr; 7(2):277-282. PubMed ID: 30301703 [TBL] [Abstract][Full Text] [Related]
14. Effectiveness and safety of oral dutasteride for male androgenetic alopecia in real clinical practice: A descriptive monocentric study. Vañó-Galván S; Saceda-Corralo D; Moreno-Arrones OM; Rodrigues-Barata R; Morales C; Gil-Redondo R; Bernárdez-Guerra C; Hermosa-Gelbard Á; Jaén-Olasolo P Dermatol Ther; 2020 Jan; 33(1):e13182. PubMed ID: 31820540 [TBL] [Abstract][Full Text] [Related]
15. Androgenetic alopecia; drug safety and therapeutic strategies. Motofei IG; Rowland DL; Baconi DL; Tampa M; Sârbu MI; Păunică S; Constantin VD; Bălălău C; Păunică I; Georgescu SR Expert Opin Drug Saf; 2018 Apr; 17(4):407-412. PubMed ID: 29363345 [TBL] [Abstract][Full Text] [Related]
16. Assessing dutasteride-associated sexual dysfunction using the U.S. Food and Drug Administration Adverse Event Reporting System. Gupta AK; Carviel J; Gupta MA; Shear NH J Eur Acad Dermatol Venereol; 2018 Aug; 32(8):1373-1376. PubMed ID: 29194783 [TBL] [Abstract][Full Text] [Related]
17. Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: A randomized controlled open-label, evaluator-blinded study. Shanshanwal SJ; Dhurat RS Indian J Dermatol Venereol Leprol; 2017; 83(1):47-54. PubMed ID: 27549867 [TBL] [Abstract][Full Text] [Related]
18. Evaluating 5 alpha reductase inhibitors for the treatment of male androgenic alopecia. Courtney A; Triwongwarant D; Chim I; Eisman S; Sinclair R Expert Opin Pharmacother; 2023; 24(18):1919-1922. PubMed ID: 37942878 [No Abstract] [Full Text] [Related]
19. The Impact of 5α-Reductase Inhibitor Use for Male Pattern Hair Loss on Men's Health. Said MA; Mehta A Curr Urol Rep; 2018 Jun; 19(8):65. PubMed ID: 29909472 [TBL] [Abstract][Full Text] [Related]
20. Cerebral Venous Sinus Thrombosis Associated with Dutasteride Use. Choi BK; Cheon K; Cho BH; Jung JW; Lee KY Yonsei Med J; 2020 Jun; 61(6):553-555. PubMed ID: 32469180 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]